Adaptive Cardiac Resynchronization Therapy (aCRT)
Study Status
Closed to Enrollment
Study Description
The Adaptive Cardiac Resynchronization Therapy (aCRT) study is a prospective, multi-center, randomized, double-blind, worldwide IDE (investigational device exemption) clinical trial designed to demonstrate the safety and efficacy of the aCRT device feature.
Cardiac resynchronization therapy (CRT) is accomplished by pacing both the left ventricle (LV) and right ventricle (RV) at short delays to provide synchronous ventricular contraction. CRT has been shown to improve clinical outcomes and survival rates and to result in reverse remodeling, a primary indicator of improved symptoms. Several studies, in fact, have shown that in CRT-indicated patients, LV pacing alone can provide similar improvements as biventricular pacing.
Several studies have demonstrated a significant correlation between cardiac function and atrioventricular (AV) and interventricular (VV) delays. Several other studies have provided evidence of the benefit of echo-guided AV and VV optimization. Optimization using echocardiography presents several challenges, including the need for different settings for resting and active stat
This study aims to demonstrate whether the aCRT feature provided in future CRT devices is equal to or an improvement upon echo optimization.
Sponsor
Medtronic
Key Eligibility
- Patient is indicated for a CRT-D implant in the next 30 days
- Intrinsic QRS duration ≥120ms within the last 30 days
- LVEF ≤35% within the last six months
Principal Investigator
Contact
- Jaquelene Morales
- (212) 746-4857
- [email protected]
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]